Immediate improvement in chronic central post-stroke pain, chronic post-stroke skin hypersensitivity, walking and right hand function following a single dose of perispinal etanercept. Treatment by Dr. Tobinick at the Institute of Neurological Recovery (INR®) in Boca Raton, Florida, on November 4, 2020, 16 months after stroke.

Text, images and video © 2020, INR PLLC, all rights reserved.

Request a consultation today

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Immediate improvement in central pain, cutaneous hypersensitivity, walking, spasticity and balance following a single dose of perispinal etanercept. Treatment by Dr. Tobinick at the Institute of Neurological Recovery (INR®) in Boca Raton, Florida, on October 30, 2020, 4 years after traumatic brain injury and stroke caused by a motorcycle accident.

Text, images and video © 2020, INR PLLC, all rights reserved.

Request a consultation today

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Immediate improvement in hand function, speech, walking, and pain, 2 years after stroke following a single dose of perispinal etanercept. Treatment by Dr. Tobinick at the Institute of Neurological Recovery (INR®) in Boca Raton, Florida, on October 28, 2020.

Text, images and video © 2020, INR PLLC, all rights reserved.

Request a consultation today

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Immediate recovery 2 1/2 years after stroke following perispinal etanercept treatment by Dr. Tobinick. Filmed at the Institute of Neurological Recovery (INR®) in Boca Raton, Florida, August, 2020.

Text, images and video © 2020, INR PLLC, all rights reserved.

Request a consultation today

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Perispinal etanercept treatment by Dr. Tobinick, years after stroke. Treatment was for chronic post-stroke neurological dysfunction, including chronic, intractable central post-stroke pain. Filmed at the Institute of Neurological Recovery (INR®) in Boca Raton, Florida, August 11, 2020.

Text, images and video © 2020, INR PLLC, all rights reserved.

Request a consultation today

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

4 years after brainstem stroke, improvements in chronic central post-stroke pain and less difficulty in swallowing immediately following perispinal etanercept treatment by Dr. Tobinick, February 28, 2020.

Text, images and video © 2020, INR PLLC, all rights reserved.

Request a consultation today

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Perispinal Etanercept RCT 2019

Gold Coast, Australia (January 3, 2020): The results of a randomized, placebo-controlled, double-blind clinical  trial of perispinal etanercept were published today, confirming the efficacy and remarkable results of perispinal etanercept in a cohort of stroke survivors with relentless, intractable daily pain after stroke. The individuals were treated an average of about 4 years after stroke and each reported constant daily pain after their stroke that had failed to adequately respond to all previous forms of treatment. They received two doses of perispinal etanercept, each two weeks apart, with the control group receiving two doses of saline administered perispinally. The control group had no change in their daily pain, but the etanercept group had a significant reduction in pain, measured at 30 days, with 30% of the etanercept patients showing near complete pain abatement after the first etanercept treatment. The study concludes: “Perispinal etanercept can provide significant and ongoing benefits for the chronic post-stroke management of pain and greater shoulder flexion by the paretic arm. Effects are rapid and highly significant, supporting direct action on brain function.”

The clinical trial results published on January 3, 2020 in the journal  Expert Opinion on Investigational Drugs. Learn More.

Video accompanying the publication, Tobinick E. Immediate Resolution of Hemispatial Neglect and Central Post-Stroke Pain After Perispinal Etanercept: Case Report. Clinical Drug Investigation. 2019. Link to article (open access) and free download

Text, images and video © 2019, Edward Tobinick. Creative Commons license 4.0.

Request a consultation today

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Rapid improvement in speech, chronic central post-stroke pain, and walking 10 years after stroke after perispinal etanercept treatment. Treatment by Edward Tobinick M.D., February 2019, at the INR in Boca Raton, Florida. strokebreakthrough.com 4K version with subtitles. Text, images and video © 2019, INR PLLC, all rights reserved.

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Rapid improvement in speech, aphasia, motor function and chronic post-stroke pain immediately following perispinal etanercept (PSE) treatment by Edward Tobinick M.D. Filmed January 2019 at the Institute of Neurological Recovery in Boca Raton, Florida. http://www.strokebreakthrough.com 4K version with subtitles. Text, images and video © 2019, INR PLLC, all rights reserved.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use